Evoke Pharma Reports Increased Sales Amid Ongoing Losses
Evoke Pharma Inc reported increased Q3 net product sales of $4.28 million, up from $2.65 million in 2024, but faced a net loss of $1.16 million due to rising operating expenses. Cash reserves decreased to $11.58 million. The company anticipates ongoing losses and is seeking additional funding to support Gimoti's commercialization and clinical trials.
Evoke Pharma Inc ( (EVOK) ) has released its Q3 earnings. Here is a breakdown of the information Evoke Pharma Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Evoke Pharma Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for gastroenterological disorders, with its primary product being Gimoti, a nasal spray for diabetic gastroparesis. In its latest earnings report, Evoke Pharma highlighted a notable increase in net product sales, reaching $4.28 million for the third quarter of 2025, compared to $2.65 million in the same period of 2024. Despite this growth, the company reported a net loss of $1.16 million for the quarter, reflecting ongoing challenges in managing operating expenses, which rose to $5.42 million. The company’s financial position shows a decrease in cash and cash equivalents to $11.58 million from $13.60 million at the end of 2024, alongside an increase in accounts payable and accrued expenses. Looking ahead, Evoke Pharma anticipates continued losses as it focuses on the commercialization of Gimoti and related clinical trials. The company acknowledges the need for additional funding to sustain operations and is exploring various financing options to support its strategic objectives.
